IN8bio (INAB)
NASDAQ:INAB
INAB Stock Chart & Stats
$1.55
-$0.04(-11.59%)
At close: 4:00 PM EST
$1.55
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.17 - $6.92
Previous CloseN/A
Volume363.43K
Average Volume (3M)74.58K
Market Cap
$16.35M
Enterprise Value-$17.13M
Total Cash (Recent Filing)$27.09M
Total Debt (Recent Filing)$2.78M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding9,847,089
10 Day Avg. Volume64,995
30 Day Avg. Volume74,576
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.60
Enterprise Value/Ebitda0.99
Forecast
1Y Price Target
$5.00Price Target Upside222.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing And RunwayRecent private financing strengthened the balance sheet and materially extended operational runway, enabling advancement of key clinical programs and regulatory-enabling studies.
Glioblastoma Clinical Data And Regulatory PathwayGlioblastoma clinical results showed meaningful gains in progression-free and overall survival, supporting plans to present data to the Food and Drug Administration to pursue potential registrational and accelerated approval pathways.
Preclinical Safety ProfilePreclinical data for the T-cell engager demonstrated comparable B-cell depletion to an existing therapy while inducing much lower levels of pro-inflammatory cytokines, suggesting a reduced risk of severe cytokine release in clinical testing.
Bears Say
Clinical, Regulatory And Commercial Execution RiskDevelopment programs face multiple material risks, including clinical setbacks, regulatory obstacles, commercialization challenges, partner collaboration failures, funding shortfalls, and intellectual property disputes that could disrupt timelines and value creation.
Financial Performance And Funding RiskThe company reports no product revenues and sustained net losses, making available cash and operational runway a central financial vulnerability that may necessitate further financing.
IN8bio News
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $1.17 and its highest was $6.92 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $16.35M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is May 07, 2026 which is in 42 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Mar 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.19.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.54.
How many shares outstanding does IN8bio have?
IN8bio has 9,847,089 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(222.58% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―